TY - JOUR T1 - VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer JF - In Vivo JO - In Vivo SP - 2641 LP - 2646 DO - 10.21873/invivo.12082 VL - 34 IS - 5 AU - TAKAAKI FUJII AU - TOMOKO HIRAKATA AU - SASAGU KUROZUMI AU - SHOKO TOKUDA AU - YUKO NAKAZAWA AU - SAYAKA OBAYASHI AU - REINA YAJIMA AU - TETSUNARI OYAMA AU - KEN SHIRABE Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2641.abstract N2 - Background/Aim: Vascular endothelial growth factor-A (VEGF-A), an important angiogenic factor, has been reported to effect cancer growth and development. Recent reports indicated that anti-VEGF therapy has an important effect of enhancing anti-tumor immunity in various cancers. In the current study, we investigated the relationship between VEGF-A expression and immunological factors, including programmed cell death ligand 1 (PD-L1) and the degrees of stromal tumor-infiltrating lymphocytes (TILs) in breast cancer. Patients and Methods: This study enrolled 97 cases with invasive breast cancer who had undergone surgery without preoperative therapy. The grades of stromal-TILs were evaluated using the criteria of the International Working Group for TILs in breast cancer: low, intermediate, and high. VEGF-A and PD-L1 positivity were evaluated by immunohistochemistry. The relationship between VEGF-A expression and the expression of PD-L1 and TILs was investigated. Results: Among the 97 cases, 37 (38.1%) had positive VEGF-A expression in the breast tumor. We divided the cases in two groups based on the VEGF-A expression levels. The analysis revealed that PD-L1 positivity was significantly associated with VEGF-A expression in the breast tumor (29.7% vs. 10.0%, p=0.014). Among the cases with positive PD-L1, 36.7% of VEGF-positive cases and none of VEGF-negative cases had low TILs in the breast tumor. Conclusion: VEGF-A expression in breast cancer may reflect PD-L1 expression in the tumor. VEGF-A may act as a negative biomarker of TILs in PD-L1-positive breast cancer. Our results suggest that VEGF-A may be predictive of immunological features and may serve as a useful biomarker for immuno-targeting therapy in patients with breast cancer. ER -